Xarelto has come under a lot of fire lately, as thousands of people have developed a deadly internal bleeding disorder after taking the anticoagulant, and more than 60 people have died. The basis of these claims are that the makers of Xarelto, Bayer and Janssen (a division of Johnson & Johnson), designed a defective drug and failed to adequately warn plaintiffs of a danger about which they knew or should have known.
Xarelto is a member a relatively new class of drugs known as New Oral Anticoagulants (NOACs), which were designed to compete with traditional blood thinning medications such as Coumadin (Warfarin). Warfarin is a blood thinner that is prescribed to many patients who suffer from a serious medical condition know as atrial fibrillation (Afib). Afib is basically an irregular heartbeat, which can lead to the formation of clots in the deep veins of the legs. If the clots break free, they can travel through the body until they puncture the lungs or cause a stroke if the blood supply to the brain is blocked. When a clot punctures a patient’s lung, this is known as a pulmonary embolism (PE). Continue reading